Depression is a prevalent and serious condition in older adults and those with cardiovascular disease. Serotonin reuptake inhibitors (SSRIs) are commonly used to treat depression, but when they’re ineffective, alternative antidepressants must be considered. Key Facts: Depression in Older Adults and Cardiovascular Patients: Affects 15-20% of patients with coronary heart disease. Limitations of SSRIs: While …
Pristiq (Desvenlafaxine) is an SNRI antidepressant developed by Wyeth as an improved successor to the older drug Effexor (Venlafaxine). Pristiq is engineered to contain solely the pharmacologically active metabolite of Venlafaxine known as “O-desmethylvenlafaxine” in a synthetic format dubbed “desvenlafaxine.” The drug was approved by the FDA in 2008 for the treatment of major depression …
Pristiq (Desvenlafaxine) is a drug that was approved for the treatment of major depression in 2007. It functions as an SNRI (serotonin-norepinephrine reuptake inhibitor) and increases extracellular levels of two neurotransmitters. In addition to treating depression, it is also being investigated as a non-hormonal approach to treating menopause. This drug is considered very similar to …
Pristiq (Desvenlafaxine) is an antidepressant drug that functions as an SNRI (Selective Serotonin Norepinephrine Reuptake Inhibitor). In other words, it prevents the reuptake of the neurotransmitter serotonin in addition to that of norepinephrine. It was created and marketed by Wyeth – a company that has now become part of Pfizer. This drug is extremely similar …